These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39073724)

  • 1. Liver Tissue Proteins Improve the Accuracy of Plasma Proteins as Biomarkers in Diagnosing Metabolic Dysfunction-Associated Steatohepatitis.
    Sourianarayanane A; Salemi MR; Phinney BS; McCullough AJ
    Proteomics Clin Appl; 2024 Jul; ():e202300236. PubMed ID: 39073724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
    Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
    JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of magnetic resonance imaging (MRI) iron corrected T1 in monitoring metabolic dysfunction-associated steatohepatitis in obesity following bariatric surgery and lifestyle modification: a prospective cohort study.
    Chiyanika C; Hui SCN; Sin DMC; Shumbayawonda E; Wong SKH; Ng EKW; Yip TC; Wong VW; Chu WCW
    Quant Imaging Med Surg; 2024 Jul; 14(7):4659-4674. PubMed ID: 39022255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.
    Iruzubieta P; Mayo R; Mincholé I; Martínez-Arranz I; Arias-Loste MT; Ibañez-Samaniego L; Ampuero J; Abad J; Martín-Mateos R; Fernández-Laso AB; Albillos A; Bañares R; Calleja JL; Romero-Gómez M; Aller R; Crespo J
    United European Gastroenterol J; 2024 Aug; ():. PubMed ID: 39099245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis.
    Tincopa MA; Loomba R
    Semin Liver Dis; 2024 Jul; ():. PubMed ID: 38981691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses.
    Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A
    Obes Facts; 2024 Jun; ():1-10. PubMed ID: 38934179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.